Credit Suisse Group restated their neutral rating on shares of Portola Pharmaceuticals (NASDAQ:PTLA) in a research note published on Wednesday morning, Briefing.com Automated Import reports.
A number of other brokerages also recently issued reports on PTLA. Cowen reissued a buy rating and set a $149.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. ValuEngine downgraded Zosano Pharma from a buy rating to a hold rating in a research report on Wednesday, May 1st. Zacks Investment Research downgraded Hersha Hospitality Trust from a buy rating to a hold rating in a research report on Thursday, May 2nd. Oppenheimer set a $42.00 price objective on Portola Pharmaceuticals and gave the stock a buy rating in a research report on Friday, April 12th. Finally, BidaskClub downgraded ZIX from a strong-buy rating to a buy rating in a research report on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. Portola Pharmaceuticals has a consensus rating of Hold and a consensus price target of $42.29.
Shares of NASDAQ:PTLA opened at $26.07 on Wednesday. The business’s 50-day simple moving average is $27.24. The company has a debt-to-equity ratio of 5.15, a current ratio of 4.81 and a quick ratio of 4.77. Portola Pharmaceuticals has a 12-month low of $14.81 and a 12-month high of $42.17.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.02). The firm had revenue of $22.17 million during the quarter, compared to the consensus estimate of $20.60 million. Portola Pharmaceuticals had a negative return on equity of 238.48% and a negative net margin of 618.46%. The company’s quarterly revenue was up 233.9% on a year-over-year basis. During the same period last year, the company earned ($1.28) EPS. On average, sell-side analysts forecast that Portola Pharmaceuticals will post -4.13 EPS for the current year.
In related news, Director Hollings Renton sold 5,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $34.45, for a total transaction of $172,250.00. Following the completion of the transaction, the director now directly owns 14,000 shares in the company, valued at approximately $482,300. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.50% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Portola Pharmaceuticals by 0.4% during the 4th quarter. BlackRock Inc. now owns 5,326,939 shares of the biopharmaceutical company’s stock valued at $103,982,000 after acquiring an additional 19,532 shares during the period. William Blair Investment Management LLC boosted its holdings in Portola Pharmaceuticals by 41.7% during the 1st quarter. William Blair Investment Management LLC now owns 4,154,870 shares of the biopharmaceutical company’s stock valued at $144,174,000 after acquiring an additional 1,222,057 shares during the period. Fiera Capital Corp purchased a new position in Portola Pharmaceuticals during the 1st quarter valued at about $53,590,000. Brandywine Global Investment Management LLC boosted its holdings in Portola Pharmaceuticals by 11.8% during the 4th quarter. Brandywine Global Investment Management LLC now owns 834,967 shares of the biopharmaceutical company’s stock valued at $16,299,000 after acquiring an additional 87,999 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Portola Pharmaceuticals by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 730,249 shares of the biopharmaceutical company’s stock valued at $14,254,000 after acquiring an additional 33,734 shares during the period.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
See Also: What is dividend yield?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.